Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (249)	7/27/2004 4:18:58 PM
From: Icebrg	Read Replies (2) of 946

>>Desite the trumpeting about the record Trisenox revenues, analysts estimates called for better earnings and revenue. This is a miss,>> The interesting question is: "Who missed? The company or the analysts?" Even if I am not particularly pleased with the comparisons they do, Trisenox sales were strong. Relatively seen. >> and I gather there was nothing new in the CC.>> There were some data on the Stellar 3 trial. According to the latest mid-July reporting 201 "events" had occurred. (Which in normal language means that 201 of the patients had died). Bianco says that the MST is above 7 months. Compared with most historical trials this is a very high figure. In some trials this patient group (i.e. patients with a Performance Status of 2) didn't even reach half of that figure. Clearly there is an effect. If it is a treatment effect or the effect of a very skewed enrollment process is still anybody's guess. Bianco claims fwiw that they are seeing similar indications of something "positive" in Stellar 2 and 4. Too early to draw any conclusions yet about the "event"rate as the trials have just concluded enrollment, but other parameters like the number of treatments given to patients is similar to what was observed in Stellar 3 and considerably higher than the "norm". Considering that biotech share prices are often primarily driven by speculations about the unknown, the Stellar-effects are so far somewhat less than stellar. We should see what happens as we approach the moment of truth sometimes early in 2005. For an overview of what could be expected in terms of MST for PS2 patients there was very recently an article by Corey Langer published in The Oncologist. Judging from the number of companies he is funded by, he seems to be something of an expert in this area. Well I guess he is. He is also represented at Medscape. "Dilemmas in Management: The Controversial Role of Chemotherapy in PS 2 Advanced NSCLC and Potential Role of CT-2103 (Xyotax)," by Corey J. Langer: theoncologist.alphamedpress.org Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next